Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204188118> ?p ?o ?g. }
- W3204188118 endingPage "100386" @default.
- W3204188118 startingPage "100386" @default.
- W3204188118 abstract "•ROCK2 inhibition with the small-molecule inhibitor KD025 prevents and reverses hepatoxin-induced liver fibrosis.•ROCK2 inhibition attenuates profibrogenic immune function.•KD025 exerts direct effects on liver macrophages resulting in decreased TNF secretion and impeded migration.•KD025 administration attenuates T cell IL-17 production and B-cell IgG production, which indirectly contributes to downregulation of profibrogenic macrophage function. Background & AimsFibrosis, the primary cause of morbidity in chronic liver disease, is induced by pro-inflammatory cytokines, immune cell infiltrates, and tissue resident cells that drive excessive myofibroblast activation, collagen production, and tissue scarring. Rho-associated kinase 2 (ROCK2) regulates key pro-fibrotic pathways involved in both inflammatory reactions and altered extracellular matrix remodelling, implicating this pathway as a potential therapeutic target.MethodsWe used the thioacetamide-induced liver fibrosis model to examine the efficacy of administration of the selective ROCK2 inhibitor KD025 to prevent or treat liver fibrosis and its impact on immune composition and function.ResultsProphylactic and therapeutic administration of KD025 effectively attenuated thioacetamide-induced liver fibrosis and promoted fibrotic regression. KD025 treatment inhibited liver macrophage tumour necrosis factor production and disrupted the macrophage niche within fibrotic septae. ROCK2 targeting in vitro directly regulated macrophage function through disruption of signal transducer and activator of transcription 3 (STAT3)/cofilin signalling pathways leading to the inhibition of pro-inflammatory cytokine production and macrophage migration. In vivo, KDO25 administration significantly reduced STAT3 phosphorylation and cofilin levels in the liver. Additionally, livers exhibited robust downregulation of immune cell infiltrates and diminished levels of retinoic acid receptor-related orphan receptor gamma (RORγt) and B-cell lymphoma 6 (Bcl6) transcription factors that correlated with a significant reduction in liver IL-17, splenic germinal centre numbers and serum IgG.ConclusionsAs IL-17 and IgG–Fc binding promote pathogenic macrophage differentiation, together our data demonstrate that ROCK2 inhibition prevents and reverses liver fibrosis through direct and indirect effects on macrophage function and highlight the therapeutic potential of ROCK2 inhibition in liver fibrosis.Lay summaryBy using a clinic-ready small-molecule inhibitor, we demonstrate that selective ROCK2 inhibition prevents and reverses hepatic fibrosis through its pleiotropic effects on pro-inflammatory immune cell function. We show that ROCK2 mediates increased IL-17 production, antibody production, and macrophage dysregulation, which together drive fibrogenesis in a model of chemical-induced liver fibrosis. Therefore, in this study, we not only highlight the therapeutic potential of ROCK2 targeting in chronic liver disease but also provide previously undocumented insights into our understanding of cellular and molecular pathways driving the liver fibrosis pathology. Fibrosis, the primary cause of morbidity in chronic liver disease, is induced by pro-inflammatory cytokines, immune cell infiltrates, and tissue resident cells that drive excessive myofibroblast activation, collagen production, and tissue scarring. Rho-associated kinase 2 (ROCK2) regulates key pro-fibrotic pathways involved in both inflammatory reactions and altered extracellular matrix remodelling, implicating this pathway as a potential therapeutic target. We used the thioacetamide-induced liver fibrosis model to examine the efficacy of administration of the selective ROCK2 inhibitor KD025 to prevent or treat liver fibrosis and its impact on immune composition and function. Prophylactic and therapeutic administration of KD025 effectively attenuated thioacetamide-induced liver fibrosis and promoted fibrotic regression. KD025 treatment inhibited liver macrophage tumour necrosis factor production and disrupted the macrophage niche within fibrotic septae. ROCK2 targeting in vitro directly regulated macrophage function through disruption of signal transducer and activator of transcription 3 (STAT3)/cofilin signalling pathways leading to the inhibition of pro-inflammatory cytokine production and macrophage migration. In vivo, KDO25 administration significantly reduced STAT3 phosphorylation and cofilin levels in the liver. Additionally, livers exhibited robust downregulation of immune cell infiltrates and diminished levels of retinoic acid receptor-related orphan receptor gamma (RORγt) and B-cell lymphoma 6 (Bcl6) transcription factors that correlated with a significant reduction in liver IL-17, splenic germinal centre numbers and serum IgG. As IL-17 and IgG–Fc binding promote pathogenic macrophage differentiation, together our data demonstrate that ROCK2 inhibition prevents and reverses liver fibrosis through direct and indirect effects on macrophage function and highlight the therapeutic potential of ROCK2 inhibition in liver fibrosis." @default.
- W3204188118 created "2021-10-11" @default.
- W3204188118 creator A5007330428 @default.
- W3204188118 creator A5012089845 @default.
- W3204188118 creator A5017454682 @default.
- W3204188118 creator A5017541508 @default.
- W3204188118 creator A5021210268 @default.
- W3204188118 creator A5024495245 @default.
- W3204188118 creator A5035282947 @default.
- W3204188118 creator A5042529968 @default.
- W3204188118 creator A5057306266 @default.
- W3204188118 creator A5058268746 @default.
- W3204188118 creator A5062183309 @default.
- W3204188118 creator A5063583921 @default.
- W3204188118 creator A5076689903 @default.
- W3204188118 creator A5077509611 @default.
- W3204188118 creator A5086464749 @default.
- W3204188118 date "2022-01-01" @default.
- W3204188118 modified "2023-09-30" @default.
- W3204188118 title "ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis" @default.
- W3204188118 cites W1895601060 @default.
- W3204188118 cites W1983081586 @default.
- W3204188118 cites W1983135466 @default.
- W3204188118 cites W1986904544 @default.
- W3204188118 cites W1997623655 @default.
- W3204188118 cites W2004107033 @default.
- W3204188118 cites W2005119615 @default.
- W3204188118 cites W2011379117 @default.
- W3204188118 cites W2017046428 @default.
- W3204188118 cites W2017893786 @default.
- W3204188118 cites W2032348735 @default.
- W3204188118 cites W2032639324 @default.
- W3204188118 cites W2038363975 @default.
- W3204188118 cites W2048612060 @default.
- W3204188118 cites W2065338955 @default.
- W3204188118 cites W2066542029 @default.
- W3204188118 cites W2069032909 @default.
- W3204188118 cites W2076277964 @default.
- W3204188118 cites W2077603983 @default.
- W3204188118 cites W2087096376 @default.
- W3204188118 cites W2102370935 @default.
- W3204188118 cites W2105227585 @default.
- W3204188118 cites W2112427741 @default.
- W3204188118 cites W2121137478 @default.
- W3204188118 cites W212348197 @default.
- W3204188118 cites W2126747605 @default.
- W3204188118 cites W2129267942 @default.
- W3204188118 cites W2155116729 @default.
- W3204188118 cites W2157537726 @default.
- W3204188118 cites W2178968673 @default.
- W3204188118 cites W2231409040 @default.
- W3204188118 cites W2316426285 @default.
- W3204188118 cites W2387461462 @default.
- W3204188118 cites W2491869734 @default.
- W3204188118 cites W2591918412 @default.
- W3204188118 cites W2740263004 @default.
- W3204188118 cites W2757949543 @default.
- W3204188118 cites W2769262718 @default.
- W3204188118 cites W2769927853 @default.
- W3204188118 cites W2774399208 @default.
- W3204188118 cites W2900396431 @default.
- W3204188118 cites W2912966881 @default.
- W3204188118 cites W2941742514 @default.
- W3204188118 cites W3030626861 @default.
- W3204188118 cites W3035322654 @default.
- W3204188118 cites W81352928 @default.
- W3204188118 doi "https://doi.org/10.1016/j.jhepr.2021.100386" @default.
- W3204188118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34917911" @default.
- W3204188118 hasPublicationYear "2022" @default.
- W3204188118 type Work @default.
- W3204188118 sameAs 3204188118 @default.
- W3204188118 citedByCount "14" @default.
- W3204188118 countsByYear W32041881182022 @default.
- W3204188118 countsByYear W32041881182023 @default.
- W3204188118 crossrefType "journal-article" @default.
- W3204188118 hasAuthorship W3204188118A5007330428 @default.
- W3204188118 hasAuthorship W3204188118A5012089845 @default.
- W3204188118 hasAuthorship W3204188118A5017454682 @default.
- W3204188118 hasAuthorship W3204188118A5017541508 @default.
- W3204188118 hasAuthorship W3204188118A5021210268 @default.
- W3204188118 hasAuthorship W3204188118A5024495245 @default.
- W3204188118 hasAuthorship W3204188118A5035282947 @default.
- W3204188118 hasAuthorship W3204188118A5042529968 @default.
- W3204188118 hasAuthorship W3204188118A5057306266 @default.
- W3204188118 hasAuthorship W3204188118A5058268746 @default.
- W3204188118 hasAuthorship W3204188118A5062183309 @default.
- W3204188118 hasAuthorship W3204188118A5063583921 @default.
- W3204188118 hasAuthorship W3204188118A5076689903 @default.
- W3204188118 hasAuthorship W3204188118A5077509611 @default.
- W3204188118 hasAuthorship W3204188118A5086464749 @default.
- W3204188118 hasBestOaLocation W32041881181 @default.
- W3204188118 hasConcept C104317684 @default.
- W3204188118 hasConcept C126322002 @default.
- W3204188118 hasConcept C127561419 @default.
- W3204188118 hasConcept C134018914 @default.
- W3204188118 hasConcept C176891718 @default.
- W3204188118 hasConcept C203014093 @default.
- W3204188118 hasConcept C2780559512 @default.